Nykode Therapeutics ASA (NYKD) — Cash Flow-to-Debt Ratio
Nykode Therapeutics ASA (NYKD) has a Cash Flow-to-Debt Ratio of -1.11x as of June 2026, meaning its operating cash flow of Nkr-6.35 Million could theoretically repay -1% of its total liabilities (Nkr5.73 Million) in one year. See NYKD financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nykode Therapeutics ASA Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Nykode Therapeutics ASA across 10 annual periods. For the full cash flow conversion analysis, see Nykode Therapeutics ASA cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Nykode Therapeutics ASA (2016–2025)
Year-by-year debt coverage analysis for Nykode Therapeutics ASA. Check Nykode Therapeutics ASA (NYKD) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.50x | Nkr-29.46 Million | Nkr8.42 Million | ▼ -18.0% |
| 2024 | -2.97x | Nkr-51.22 Million | Nkr17.27 Million | ▼ -13.4% |
| 2023 | -2.62x | Nkr-96.62 Million | Nkr36.93 Million | ▼ -715.1% |
| 2022 | -0.32x | Nkr-20.69 Million | Nkr64.46 Million | ▼ -2087.3% |
| 2021 | 0.02x | Nkr1.16 Million | Nkr71.50 Million | ▼ -99.5% |
| 2020 | 3.52x | Nkr180.27 Million | Nkr51.18 Million | ▲ +293.3% |
| 2019 | -1.82x | Nkr-92.08 Million | Nkr50.52 Million | ▲ +61.5% |
| 2018 | -4.73x | Nkr-62.78 Million | Nkr13.27 Million | ▲ +17.6% |
| 2017 | -5.74x | Nkr-62.78 Million | Nkr10.94 Million | ▼ -525.2% |
| 2016 | -0.92x | Nkr-1.60 Million | Nkr1.74 Million | — |